Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05221320 · ClinicalTrials.gov registry record · Phase 2
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
A Phase 2 study, sponsored by BioMed Valley Discoveries.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT05221320 is a Phase 2 study that was terminated before completion, run by BioMed Valley Discoveries. The registered enrollment target is 47 participants.
The verdict
NCT05221320, a Phase 2 study, was terminated before completion, sponsored by BioMed Valley Discoveries.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed eligible for trial participation. Each disease-based basket will open to enrollment in two-stages. The opening of stage two will be dependent on the observed responses in the patients enrolled in the first stage.
Interventions
- DRUG Ulixertinib
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2022-05-26 |
| Est. Completion | 2024-07-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05221320
The ClinicalTrials.gov registry entry for NCT05221320 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ulixertinib is the first listed.
NCT05221320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05221320 about?
NCT05221320 is a clinical study titled "Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies". This is an open-label, prospective phase two basket trial assessing the efficacy of ulixertinib in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies. All patients enrolled must have a mitogen-activated protein kinase (MAPK) activating mutation to be deemed e...
What is the current status of trial NCT05221320?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2022-05-26. Estimated completion is 2024-07-14.
What interventions are being tested in trial NCT05221320?
The interventions under investigation include: Ulixertinib (DRUG), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT05221320?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.